The Latest Breaking News from DGX

Quest Diagnostics Inc (NYSE:DGX) posted a better-than-expected Q1 FY22 adjusted EPS of $3.22, down 14.4% Y/Y, beating the consensus of $2.97. Sales came in at $2.61 billion, a decline of 4% Y/Y, slightly lower than the Wall Street estimate of $2.63 billion. COVID-19 testing revenues fell 27.6% to $599 million, while Base…

The Centers for Disease Control and Prevention (CDC) has granted a contract to Quest Diagnostics Inc (NYSE:DGX) to perform testing and provide laboratory data analysis to help identify patterns in SARS-COV-2 seroprevalence on a multistate basis.  Quest was awarded the contract following a competitive bid. The total contract value with all options is valued…

If history is any guide, there may be trouble ahead for shares of Quest Diagnostics (NYSE:DGX). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

The healthcare industry is expected to achieve solid growth with rising investments in the sector and soaring demand from an aging population. Therefore, we think it could be wise to bet on beaten-down healthcare stocks West Pharmaceutical (WST), Bio-Rad Laboratories (BIO), Quest Diagnostics (DGX), and Masimo Corporation (MASI), which possess…